|
Paul Hastings is President and Chief Executive Officer of OncoMed. Prior, he was President, Chief Executive Officer and a Director of QLT, Inc. Before joining QLT in February 2002, Mr. Hastings was President, CEO, and a Director of Axys Pharmaceuticals, Inc., where he was responsible for leading the strategic acquisition of Axys by Celera Corporation. Since starting his career in 1984 with F. Hoffman-La Roche, Mr. Hastings has held various positions of increasing responsibility with notable biotech and pharmaceutical companies, including Vice President, Marketing and Sales and European General Manager, Synergen Inc.; Vice President, Global Marketing, Genzyme Corporation; President, Genzyme Therapeutics Europe; President, Genzyme Therapeutics Worldwide; and President, Chiron BioPharmaceuticals. Mr. Hastings holds a BS from the University of Rhode Island. He is also a member of several boards of directors including Viacell Inc. (Nasdaq: VIAC), Arriva Pharmaceuticals, Inc., and BC Leading Edge Endowment Fund. | 